Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

The HARMONY trial is an interventional trial enrolling metastatic breast cancer (MBC). Current treatment of breast cancer uses clinical subtype information (e.g. hormone receptor-positive (HR+)) to help guide treatment options. Breast cancer can also be characterized by molecular subtype, but it is not known if this information is helpful in determining treatment when breast cancer has become metastatic. HARMONY will give the treating physician of each participant the molecular subtype of the tumor based on PAM50 testing. The usefulness of this information will be determined through the physic

Trial Details

NCT ID
NCT03769415
Phase
NA
Sponsor
UNC Lineberger Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Intrinsic Subtyping of Primary Breast Cancer
Locations (sample)
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584
  • Raleigh, North Carolina, United States|35.7721,-78.63861

Key Eligibility Criteria

  • Women or men at least 18 years of age
  • Pathologically documented diagnosis of measurable or evaluable metastatic breast cancer with known ER, PR, and HER2 status determined by the local …
  • Enrolled before or during first line of treatment for metastatic breast cancer. No more than 1 prior line of therapy in the metastatic setting.
  • Accessible medical records for all treatment and response data in the metastatic setting.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →